Michael Buschle

Director/Board Member at VICORE PHARMA HOLDING AB

66 year

Health Technology

Finance

Consumer Services

Profile

Michael Buschle was the founder of Intercell AG, serving as Chief Scientific Officer from 1997 to 2012.
Current jobs include Director at Vicore Pharma Holding AB since 2023 and Advisor at HBM Partners AG since 2017.
Former jobs include Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2018 and Chief Scientific Officer at Glenmark Pharmaceuticals Ltd. Education includes a doctorate from the University of London.

Michael Buschle active positions

Companies	Position	Start
VICORE PHARMA HOLDING AB	Director/Board Member	01/01/2023
HBM Partners AG HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million.	Private Equity Investor	01/01/2017

All active positions of Michael Buschle

Former positions of Michael Buschle

Companies	Position	End
YMAS THER	Director/Board Member	11/12/2018
Intercell AG Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines	Founder	01/01/2012
GLENMARK PHARMACEUTICALS LIMITED	Chief Tech/Sci/R&D Officer	-

See the detail of Michael Buschle's experience

Training of Michael Buschle

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Buschle's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
HBM Partners AG HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million.	Finance
Intercell AG Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines	Health Technology
Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals	Health Technology
University of London University of London Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Vicore Pharma Holding AB Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases	Health Technology
Y-mAbs Therapeutics, Inc. Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer	Health Technology